Aims: Cytochrome P450 (CYP450) 2D6 is an important member of the P450 enzyme superfamily and responsible for clearing 25% of clinically important drugs. The aim of this study was to assess the catalytic characteristics of 24 CYP2D6 allelic isoforms found in the Chinese population and their effects on the metabolism of risperidone in vitro.
Methods: Insect microsomes expressing wild-type CYP2D6 and 24 CYP2D6 allelic variants were incubated with 20-1,000 μmol/l risperidone for 40 min at 37°C. After termination, risperidone and 9-OH risperidone, the metabolite of risperidone, were precipitated and used for signal collection by ultra-performance liquid-chromatography tandem mass spectrometry.
Results: Among 24 CYP2D6 variants tested, 2 variants (CYP2D6*92 and CYP2D6*96) were found to be with no detectable activity. Two variants (E215K and R440C) exhibited higher intrinsic clearance values than the wild-type protein, while the remaining 20 CYP2D6 allelic variants exhibited significantly decreased clearance values (2.01-87.56%) compared to CYP2D6*1.
Conclusion: These findings suggest that more attention should be directed to subjects carrying these infrequent CYP2D6 alleles when administering risperidone in the clinic. This is the first report of all these novel alleles for risperidone metabolism, providing fundamental data for further clinical studies on CYP2D6 alleles.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000441007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacogenomic profiling of the South Korean population: Insights and implications for personalized medicine.
Front Pharmacol
December 2024
Seoul National University Biomedical Informatics (SNUBI), Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.
Adverse drug reactions (ADRs) pose substantial public health issues, necessitating population-specific characterization due to variations in pharmacogenes. This study delineates the pharmacogenomic (PGx) landscape of the South Korean (SKR) population, focusing on 21 core pharmacogenes. Whole genome sequencing (WGS) was conducted on 396 individuals, including 99 healthy volunteers, 95 patients with chronic diseases, 81 with colon cancer, 81 with breast cancer, and 40 with gastric cancer, to identify genotype-specific drug dosing recommendations.
View Article and Find Full Text PDFAfro-Latin American Pharmacogenetics of , , and in Dominicans: A Study from the RIBEF-CEIBA Consortium.
Pharmaceutics
October 2024
Faculty of Medicine and Health Sciences, University Institute for Bio-Sanitary Research of Extremadura INUBE, University of Extremadura, 06006 Badajoz, Spain.
: Research on pharmacogenetic variability in response to prescribed drugs and across ethnic groups is essential for personalized medicine, particularly in admixed and unstudied populations. For the first time, this study examines , , and alleles and genotypes in 197 healthy volunteers from the Dominican Republic, as part of the RIBEF-CEIBA collaborative network. : The analysis focuses on the participants' tri-hybrid genomic ancestry, with CYP alleles determined by real-time PCR and molecular ancestry inferred using 90 AIMs.
View Article and Find Full Text PDFPharmacogenomics in Sri Lanka: a comprehensive systematic review of the research landscape and clinical implications.
Pharmacogenomics
November 2024
Department of Anatomy, Genetics & Biomedical Informatics, Faculty of Medicine, University of Colombo, Sri Lanka.
Article Synopsis
- Pharmacogenomics is gaining traction in South Asia, particularly in Sri Lanka, aiming to enhance drug therapies and minimize side effects for patients.
- A comprehensive review analyzed research in Sri Lanka, where studies were classified into categories like clinical correlational, descriptive, and novel assay development; 11 articles and 8 theses were reviewed.
- While progress has been made, additional clinical studies and a wider scope of genomic research are necessary, alongside efforts to address challenges like funding and public awareness, to successfully implement personalized medicine in the region.
The impact of CYP2D6 on donepezil concentration and its lack of effect on the treatment response and adverse effect in Korean patients with Alzheimer's disease.
Korean J Physiol Pharmacol
November 2024
Research Institute of Medical Science, Konkuk University of Medicine, Seoul 05030, Korea.
Article Synopsis
- Donepezil, a medication for Alzheimer's disease, shows varied effectiveness among patients, prompting this study to explore how genetic variations in the CYP2D6 gene affect its efficacy and side effects in Koreans with AD dementia.
- The study involved 76 patients on different doses of donepezil and identified 9 CYP2D6 genetic variants, analyzing their impact on drug concentration and cognitive performance over three years.
- Results indicated that while donepezil concentrations differed based on genetic makeup, this variation did not correlate with cognitive improvements or adverse events, highlighting the need for further research on genetic influences in treatment outcomes.
Sex-Dependent Effects of CYP2D6 on the Pharmacokinetics of Berberine in Humans.
Clin Pharmacol Ther
January 2025
Department of General Pharmacology, Institute of Pharmacology, University Medicine Greifswald, Greifswald, Germany.
An over-the-counter product berberine (a major alkaloid in goldenseal) is a substrate of the uptake transporter OCT1 and the metabolizing enzyme CYP2D6. The two genes exhibit common functional polymorphisms. Approximately 9% of Europeans and white Americans are either poor CYP2D6 metabolizers or poor OCT1 transporters.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!